Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Microban launches Ascera™: a patent-pending, cutting-edge antimicrobial technology inspired by nature

Microban International

Microban International is pleased to introduce its latest ground-breaking technology – Ascera™. This patent-pending, next generation antimicrobial technology uses an active ingredient inspired by nature*, and is designed for use in olefinic polymers and solvent-based coatings. Ascera is sustainable, metal free and less toxic than alternative technologies, and provides the lifelong antimicrobial product protection that Microban is known for around the world. As the global leader in antimicrobial and odor-control technologies, Microban is committed to the development of solutions that support product sustainability by extending their useful lifetimes. Ascera exemplifies the company’s commitment to sustainability by offering lasting product protection while maintaining critical attributes, such as ease of incorporation, safe handling, and good chemical, thermal and UV stability. Ascera will perform for the product’s expected lifetime when applied according to Microban’s standards, effectively inhibiting the growth of odor-causing bacteria to prevent stains and premature aging of the finished product. “Microban has always led the antimicrobial industry with technological innovations that contribute to product sustainability,” said Dr. Souvik Nandi, Vice President of R&D at Microban International. “In the past decade, regulatory and environmental groups have put increasing pressure on many of the antimicrobial chemistries that are currently used. As a result, Microban has invested significant resources in identifying naturally occurring solutions that are more sustainable and effective. We are very proud to roll out Ascera, which represents the culmination of many years of intensive research. This is the first of an exciting series of nature-inspired solutions that we will be launching in the next few years for different market segments and material types.” “As the global leader in antimicrobial, odor-control and surface modification solutions, Microban is always standing at the forefront of the industry. As we work towards our vision of becoming the most trusted brand in ultimate cleanliness and product protection, we want the world to rely on Microban for best-in-class solutions.” Michael Ruby, President of Microban International, said. “Our R&D teams are laser-focused on developing a range of cutting-edge technologies that are nature inspired for the different market sectors we serve. Our partners look to us first for what is next. Ascera will help leading brands to create clean, odor-free and high value end-use products, which their customers will choose to support sustainability and live a clean and refreshing lifestyle." Ascera is available to manufacturers in the U.S. and Asia, along with Microban’s support and expertise. Find out more at https://www.microban.com/antimicrobial-solutions/technologies/ascera and get in touch with a representative today! *The Microban® technology used in this product is similar to acids found in nature and is used in multiple consumer product applications Contact Details Audrey Jestin at kdm communications limited, St Neots, UK +44 1480 405333 ideas@kdm-communications.com Company Website https://www.microban.com/

September 13, 2023 10:00 AM Eastern Daylight Time

Poolbeg Pharma "moving forward rapidly" with POLB001

Poolbeg Pharma PLC

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing the pharma & biotech's interim results for the six months to 30 June 2023. Skillington highlights Poolbeg's "healthy" financial position and attributes it to low operational cash burn and strong financial discipline. Skillington also emphasises cost-effective R&D, citing examples like the LPS challenge study and AI programs that utilise supercomputers for efficiency. They continue to seek non-diluted funding opportunities to support infectious disease programs, following a €2.3 million grant from the Irish government in 2022 for an oral vaccine program. Operational achievements include positive results from a POLB001 LPS human challenge trial, showing potential in treating acute inflammatory conditions and oncology-related issues. The company's collaboration with CytoReason identified valuable drug targets for influenza treatment. Additionally, progress was noted in oral vaccine delivery and clinical trials for an oral GLP-1 agonist. Skillington hinted at new indications for POLB001 in the oncology sector, addressing cytokine release syndrome, a significant market opportunity. Future milestones include RSV dataset validation, oral vaccine encapsulation, and influenza drug target validation. The company remains focused on clinical trial preparations and partnerships with pharmaceutical companies, reflecting a proactive approach to advancing their programs. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 13, 2023 08:58 AM Eastern Daylight Time

Video

News Release

Willow Bioscience eyes another use for BioOxi platform with R&D of ursodeoxycholic acid

Willow Biosciences Inc.

Willow Bioscience CEO Dr Chris Savile joined Steve Darling from Proactive to announce some significant developments within the company. Willow Bioscience specializes in the production of ursodeoxycholic acid (UDCA), a vital pharmaceutical ingredient with extensive applications in nutraceutical and pharmaceutical products. UDCA is notably used in the management and treatment of cholestatic liver diseases and gallstone conditions. Moreover, it serves as a crucial intermediate compound for tauroursodeoxycholic acid (TUDCA), an essential active pharmaceutical ingredient in a recently approved combination therapy for the treatment of ALS in Canada and the United States. In partnership with Sandhill One, LLC, Willow has successfully completed research and development on its UDCA program. This collaborative initiative enabled Willow to optimize a proprietary enzyme necessary for UDCA development. Of particular significance is the achievement of selective C-H hydroxylation at an industrial scale, often regarded as a challenging feat in the field of chemistry. Dr Savile's announcement also extended to the financial front. Willow Bioscience is initiating an offering of convertible debenture units in a non-brokered private placement to raise approximately $1.2 million. Notably, insiders, including members of the Board of Directors and senior management, are expected to subscribe to approximately 50% of the total funds raised. This underscores the strong commitment and confidence that the company's leadership has in Willow's vision and future prospects. These developments indicate that Willow Bioscience is making significant strides in its mission to advance pharmaceutical research and contribute to the development of innovative therapies and treatment options. With a focus on expanding its product portfolio and securing essential funding, the company is poised to play a pivotal role in the pharmaceutical and nutraceutical industries. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

September 12, 2023 01:39 PM Eastern Daylight Time

Video

News Release

Cannabis As Effective As Opioids for Treating Neuropathy Pain, Say Respondents to New Survey

NuggMD

Cannabis may be as effective at treating symptoms of neuropathy as are addictive drugs such as opioids, according to the results of a new survey from NuggMD, the largest telehealth platform for cannabis. Furthermore, according to respondent data, the potency of the cannabis used to treat the condition is more predictive of pain relief than any other variable, including frequency of consumption. This data calls into question the validity of previous research on this subject that used low-potency cannabis. Conducted earlier this year, the survey polled 9,700 cannabis users who have neuropathy and received 603 responses, achieving a confidence level of 95 percent with a 3.87 percent margin of error. The findings were first reported in the cannabis industry outlet Marijuana Moment. Neuropathy is a painful neurological condition that results from nerve damage. The risk of developing neuropathy generally increases with age, and addictive opioids are frequently prescribed to treat its symptoms. However, 10 states list neuropathy as a qualifying medical condition for medicinal cannabis recommendations, and many other states have legal statutes that make cannabis a treatment option for patients who have the condition. “We were not surprised that respondents told us that cannabis is effective for pain relief. What we were surprised by is how much of a factor potency plays in providing that relief among the population that we surveyed,” said Alex Milligan, co-founder and CMO of NuggMD. “Potency may be a more important variable than is commonly understood. We hope that future research further explores the potency factor.” The NuggMD survey included respondents who reported using cannabis with more than 20 percent THC, a potency that is common in both the medical and recreational markets. These respondents reported the greatest levels of relief among survey participants. The positive correlation between potency and pain relief in this survey calls into question the validity of prior studies that used government-grown cannabis, which is generally much lower in potency. Until 2021, government researchers were hamstrung by federal regulations that allowed them to use cannabis from just one source in their research. By contrast, there are many thousands of cannabis varieties available in legal markets, many of which may produce unique clinical effects because of varying chemical profiles, terpenes, and potencies. The NuggMD survey is not a peer-reviewed study and it contains selection bias. It does not provide causal evidence of cannabis being effective in the treatment of neuropathic pain. Further research into this subject by medical professionals is necessary. NuggMD’s report on the survey was written by Alexandra Arnett, MS, fact-checked by NuggMD legal and policy researcher Deb Tharp, and medically reviewed by Dr. Brian Kessler. The company can provide the full data set of its work to journalists and third-party researchers upon request. About NuggMD NuggMD is the nation's largest medical marijuana technology platform, serving patients in California, Connecticut, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com. Contact Details Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

September 12, 2023 12:23 PM Eastern Daylight Time

Itaconix targeting "very aggressive growth" during remainder of 2023

Itaconix PLC

Itaconix PLC (LSE:ITX, OTCQB:ITXXF) CEO John Shaw speaks to Thomas Warner from Proactive London after the sustainable plant-based polymer company announced its unaudited interim results for the six months ended 30 June 2023. Shaw gives an overview of the interims, highlighting the achievement of $4 million in revenues, marking their fifth consecutive record. Gross profit margins also increased, and he says the company boasts ample cash reserves for future growth initiatives. Shaw emphasises the significance of growth within their existing customer base, underscoring their commitment to providing a competitive edge through specialty ingredients. Board changes during the reporting period include the addition of seasoned CFO Paul LeBlanc and the appointment of Dr. Peter Nieuwenhuizen as permanent chair. Looking ahead, he says Itaconix aims to secure more consumer brands, with a focus on smaller accounts for sustained revenue growth. Recent fundraising efforts position the company to pursue larger ventures, particularly in the Velafresh and plant-based super absorbent sectors. Shaw anticipates aggressive growth for the remainder of the calendar year, emphasising increased profitability and resources for major new initiatives. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 12, 2023 09:51 AM Eastern Daylight Time

Video

hVIVO has "the perfect opportunity" after strong first half

hVIVO PLC

hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Thomas Warner from Proactive after the specialist contract research organisation announced its interim results for the six months to 30 June. Khan gives an overview of the results, highlighting an increase in revenues and margins that he attributes in part to an uptick in human challenge trials and their scale. Operational efficiency initiatives are also contributing positively to profit margins. He adds that the order book remains robust and that the company is in a strong cash position, holding around £31mln. The company is diversifying services, introducing new challenge models, and exploring additional revenue streams through partnerships for volunteer repurposing and lab services expansion. He also touches on hVIVO's move to Canary Wharf which he says promises an increase in capacity and efficiency. He suggests that the move creates "the perfect opportunity" for hVIVO to lock in future growth. He concludes by talking about full-year guidance and a new dividend. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 12, 2023 08:57 AM Eastern Daylight Time

Video

Tiziana Life Sciences' Alzheimer's treatment validated in new study

Tiziana Life Sciences PLC

Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company announced the publication of a new study into the potential use of its Foralumab nasal spray as a treatment for Alzheimer's disease. David explains that the study has been published in the Proceedings of the National Academy of Science (PNAS) journal and demonstrated significant improvements in Alzheimer's-related factors independent of amyloid beta and tau protein. He highlights the importance of this development in the context of Alzheimer's treatmentm saying that while current FDA-approved drugs target amyloid beta and tau protein, Foralumab takes a unique approach by resetting activated microglia in the brain to a baseline state. This novel approach offers hope for Alzheimer's patients, a disease that continues to devastate lives worldwide. Although the ultimate impact of Foralumab in the fight against Alzheimer's remains uncertain pending Phase II data, the promising results suggest it could become a vital player in the quest for effective treatments. With personal connections to Alzheimer's, Davis expresses his dedication to advancing solutions for this devastating disease, emphasising the importance of diverse approaches. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

September 12, 2023 08:19 AM Eastern Daylight Time

Video

Doceree launches The NEXT Marketing Lab – a data innovation opportunity for pharma marketers – at Digital Pharma East 2023

Doceree Inc

Doceree, a global platform building unprecedented solutions for HCP programmatic marketing with proprietary data tools, today announced yet another pathbreaking measure for the life sciences industry, The NEXT Marketing Lab. The innovation lab dedicates itself to addressing one of the most pressing challenges in the pharmaceutical sector: data intricacies, especially rigid data silos, that hinder commercial team collaboration, informed decision-making, next-gen research and clinical transformation. Curated for Doceree clients, who will gain exclusive access to the solution, The NEXT Marketing Lab will use proprietary cross-functional collaboration methodologies to identify tailored, next generation data strategies and solutions that maximize outcomes. As a well-known global pharma tech company built around proprietary technology and data tools, Doceree aims to revolutionize data solutions that marketing, sales and access teams can use to plan, deliver, and scale HCP communications backed by timely actionable insights. “The pharma landscape has evolved drastically with the industry waking up to the new reality of digital and incorporating the same into its fold to target HCPs across online platforms. The new scenario is a lot different from how data was traditionally collected in a controlled manner. The digital push has led to innumerable, vast and unstructured HCP datasets that are difficult to exploit for valuable insights that can drive key business decisions to make HCP communications more effective in terms of precision, timing and relevancy,” said Harshit Jain MD, Founder & Global CEO, Doceree. “We are guided by the vision of transforming the pharma messaging landscape. It is with this intent we have launched our latest initiative to break big data silos and bring value to pharma marketing by structuring scattered datapoints. As opposed to how unreal big data in the pharma sector may have looked, it is now a reality the industry can’t escape, and its potential can’t be ignored. The lab will greatly facilitate marketers to use and share data with ease and work with HCP datasets holistically to enhance internal and external collaborations to support innovation. This is the kind of value creation we aim to make for our partners as we assist them in their business growth.” Backed by a team of experts with extensive experience in pharmaceutical marketing, medical, consulting, data science, and technology, Doceree will engage with life sciences companies to explore and customize data strategies and solutions that align to their unique needs. The NEXT Marketing Lab collaborations can be tailored to tackle diverse challenges, such as cross-functional insight sharing, reliable HCP behavior modeling, physician-level personalization and compliant RWD integration. Cross-functional collaboration executed within a well-designed process is key to unlocking change. The NEXT Marketing Lab will use Doceree’s proprietary 4D™ methodology to: Decipher the most pressing commercial challenges impacted by data limitations. Decode relevant and viable data solutions. Decide what to prioritize based on impact and feasibility. Deliver a phased roadmap to achieve goals. “Doceree’s The NEXT Marketing Lab is designed to help marketers not only explore transformational data opportunities, but also to cross the chasm between innovative ideas and impactful market solutions,” said Kate Miller, Executive Vice President of Strategy at Doceree. “At Doceree, our mission is to push how data and technology can enhance the digital experience for the benefit of healthcare providers and their patients. The NEXT Marketing Lab is a significant milestone in fulfilling this vision.” For inquiries about Doceree’s The NEXT Marketing Lab, please contact partner@doceree.com Doceree is a global platform building unprecedented solutions for healthcare professional (HCP) programmatic messaging with proprietary data tools. It facilitates messaging between life sciences brands and HCPs through an extensive global network of digital endemic and point-of-care platforms to programmatically deliver personalized communications to HCPs and transparent marketing campaign metrics at scale. To learn more, visit doceree.com. Contact Details Priyanka Bhasin +91 78387 03702 priyanka.bhasin@doceree.com Company Website https://doceree.com/us/

September 12, 2023 07:42 AM Eastern Daylight Time

Image

Unleashing Pet Industry Trends to Keep Your Furry Friend Healthy, Happy & Pampered

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/Z2YHiW3ehKw Pets are undeniably cherished members of our families and ensuring their happiness, health and comfort is a top priority. In today's world, our furry, feathered, and scaly companions live the good life alongside us, and we strive to provide them with the very best—from their favorite treats to specialized diets, stylish collars, interactive toys and even high-tech gadgets. But what's the next big thing for your beloved pet? That's where SUPERZOO comes in, the pet industry's premier retail event that sets the stage for the latest trends and groundbreaking new products ready to elevate your pet's lifestyle to new heights! With pet spending on the rise, the range of trending products is ever-expanding—from pet health solutions and grooming tools to groundbreaking advancements featuring automation and artificial intelligence, the possibilities to enhance your pet's life are endless. A nationwide media tour was conducted to discuss these topics and more live from the Mandalay Bay Convention Center in Las Vegas, where SUPERZOO took center stage. Organized by the World Pet Association, SUPERZOO is the pet industry’s largest and most comprehensive pet retail event in North America. Topics that were discussed during the media tour included: The latest pet product news and industry insights live from SUPERZOO Pet products that will be hitting retail shelves later this year How technology is taking pet care to the next level What’s next in pet health and wellness trends, including unique foods and diets, specialized supplements, creative habitats and more For more information, visit www.SUPERZOO.org Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

September 11, 2023 02:15 PM Eastern Daylight Time

Video

1 ... 51 52 53 54 55 ... 211